substance-use-disorder
(4)
Marigold Health
Marigold Health is a Boston-based digital behavioral health company that combines certified peer recovery coaches with a 24/7 anonymous, text-based support community. Natural language processing scans member conversations to flag emerging needs and route human support where it matters most, helping people with mental health and substance use conditions stay engaged in recovery. Marigold contracts primarily with Medicaid and dual-eligible health plans under value-based arrangements, and became the largest provider of peer recovery supports in Delaware.
Gallus Detox and Recovery Services
Gallus Detox and Recovery Services is a physician-founded medical detoxification and addiction-recovery company that treats withdrawal from opioids, alcohol, benzodiazepines and other drugs in upscale, hotel-like inpatient suites staffed 24/7. Built on the proprietary 'Gallus Method' developed by ER physician Dr. Patrick Gallus in 2011, the company uses IV and injectable medications and cardiac telemetry to make detox safer and more comfortable, and reports that roughly 87% of its patients step directly into aftercare - far above the industry norm. Now led by Chairman and CEO Warren Olsen after a 2019 acquisition by SCB Global Healthcare, Gallus operates inpatient centers in Colorado, Arizona and Texas plus outpatient (IOP) services.
Recover
Recover is a San Diego-based, tech-enabled substance use treatment provider that combines medication-assisted treatment with counseling delivered via telehealth. Founded in 2021 by Nick Gulino and a former McKinsey team out of Y Combinator's Winter 2021 batch, the company partners with state and local governments to offer same-day, no-waitlist addiction care - in-network with Medi-Cal and certified by California's Department of Health Care Services - at roughly a tenth of the cost of traditional rehab facilities.
Newleos Therapeutics
Newleos Therapeutics is a Boston-based, clinical-stage biotechnology company building a new generation of treatments for neuropsychiatric disorders. Launched in February 2025 with an oversubscribed $93.5 million Series A, the company in-licensed four clinical-ready oral small molecules from Roche - targeting GABAA-y1, V1a, TAAR1, and GABAA-a5 - aimed at generalized anxiety, social anxiety, substance use disorders, and cognitive impairment. Its name nods to 'eos,' the Greek word for dawn: a new dawn for mental health treatment.